celgene corporation - BMS pharma - bristol myers squibb台灣

TWD 71.32

Bristol-Myers Squibb to Acquire Celgene to Create a

Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion.

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide)

Celgene Corporation, 86 Morris avenue SUMMIT NJ 07901 UNITED STATES, Phone 1: 190 86 73 90 00, More information.

鉅亨美股頻道提供你最完整的CELG - Celgene Corporation (賽爾基因公司)、美股公司資料、美股股票代號、美股新聞、股價走勢、技術線圖、財報分析、外資分析師評等、

Celgene Corporation(CELG.US)成立於1980年，總部位於紐澤西州的薩米特市。在全球從事發現、開發和商業化癌症和發炎性疾病的治療。

A leading biopharma company, ideally positioned to discover, develop and deliver innovative medicines for patients fighting serious diseases.